$SMMT News

Last published 1w ago

1w agoSMMTSummit Therapeutics Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 5.03 Item 5.07 Item 9.01
2w agoSMMTIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaBusiness WireFirst Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in BTC Ivonescimab Plus
2w agoSMMTLunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentPR NewswireResearch Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment BiologySEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit
2w agoSMMTSummit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology DevelopmentBusiness WireResearch Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology Summit Therapeutics Inc. (NASDAQ:SMMT) and Lunit Inc.
3w agoSMMTIvonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026Business WireHighlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab Summit Therapeutics Inc. (NASDAQ:SMMT) today announced that ivonescimab data will be featured in numerous presentations at
3w agoSMMTAkeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerPR NewswireBecomes the 7th International Registrational Clinical Trial for IvonescimabClinical Trial Site Activations in the United States Expected to Begin Q4 2026HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX:
3w agoSMMTSummit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract CancerBusiness WireClinical Trial Site Activations in the United States Expected to Begin Q4 2026 Summit Therapeutics Inc. (NASDAQ:SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group
3w agoSMMTSummit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell CarcinomaBusiness WireSMT112-216 Is a Randomized Multiregional Phase II Study Evaluating Ivonescimab Alone and in Combination with Cadonilimab or Ipilimumab in Previously Untreated Advanced ccRCC Study Is Being Conducted in Collaboration
1mo agoGILD SMMT AZN MRKAstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investmentCNBCPascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
1mo agoSMMT AZNAstraZeneca Completes $2 Billion Equity Investment in Summit TherapeuticsBusiness WireSummit Therapeutics Inc. (NASDAQ:SMMT) today announced the successful closing of AstraZeneca’s (NYSE:AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the
1mo agoNVS NVO AZN-GB GSK+3Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar dealsCNBCWestern biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
1mo agoSMMT AZNSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayBusiness WireCollaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer Summit Therapeutics Inc.
1mo agoTSX:4568 AZN SMMTDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesBusiness WireDaiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE:AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (NASDAQ:SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination
1mo agoSMMT AZNAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsBusiness WireInvestment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into
1mo agoSMMTHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026Business WireHARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates
1mo agoSMMTUpdated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian PatientsBusiness WireSustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consistent across Geographic Regions; No New Safety Signals Observed Akeso-Sponsored HARMONi-2 OS Data Also Presented at WCLC 2026; Additional
2mo agoSMMTIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in ChinaBusiness WireIvonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is
2mo agoSMMTIvonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in ChinaBusiness WireSummit is Conducting HARMONi-7 in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the
2mo agoSMMTIvonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in ChinaBusiness WireHARMONi-GI1 Conducted in China by Akeso Is First Known Phase III Study in Advanced BTC to Demonstrate OS Superiority vs. Anti-PD-(L)1 Plus Chemotherapy First Phase III Ivonescimab Readout beyond NSCLC Demonstrates
2mo agoSMMTIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet OncologyBusiness WireFirst Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI Progression Updated OS Data
3mo agoSMMTIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung CancerBusiness WireMarks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known
3mo agoSMMTLowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary DutyGlobeNewswireNEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating whether certain officers and directors of Summit Therapeutics
3mo agoSMMTSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder CancerBusiness WireHARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC Clinical Trial Site Activations Globally
3mo agoSMMTKuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ:...
3mo agoSMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026Business WireConsistent Overall Survival Observed in Western, Asian Patients in Updated Analysis from Phase III HARMONi Study in EGFRm NSCLC Post-TKI Setting for Ivonescimab Plus Chemotherapy vs. Chemotherapy Ivonescimab Plus
3mo agoSMMT RCUSArcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBusiness WireData Expected to Be Generated by Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
3mo agoRCUS SMMTArcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBusiness WireData Expected to Be Generated by Mid-2027 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people
3mo agoSMMTIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi StudyBusiness WireWestern Patients Achieved OS HR of 0.76, Consistent with Asian Patients in this Global Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) today announced results of an updated overall survival (OS) analysis from
3mo agoSMMTKuehn Law Encourages Investors of Summit Therapeutics Inc. to Contact Law FirmGlobeNewswireNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Summit Therapeutics Inc. (NASDAQ:SMMT) breached their
3mo agoSMMTSummit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026Business WireConference Call to Be Held at 4:30 p.m. EDT Summit Therapeutics Inc. (NASDAQ:SMMT) will host a conference call to announce its second quarter 2026 financial results and provide an update on operational progress on
4mo agoSMMTSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.Business WireSummit Therapeutics Inc. (NASDAQ:SMMT) today announced it has signed an agreement with Toronto-based Biossil, Inc. for the sale of ridinilazole, an investigational Phase III precision antibiotic owned by Summit.
4mo agoBNTX SMMT CGON NTHIThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionGlobeNewswireDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on
5mo agoSMMTSummit Therapeutics Announces Proposed Public Offering of Common StockBusiness WireSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the
5mo agoSMMTSummit Therapeutics - 1764383 - Summit TherapeuticsEarnings Call TranscriptsGreat. Good morning, everyone. It's my pleasure to introduce the Summit Therapeutics team. With us, we have Bob Duggan, co-CEO with Meki Sengane, co‑CEO, Manmeet Soni, CFO, Alan Yang, CRDSO, and Dave Gengar's CBSO. To st
5mo agoSMMTSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare ConferenceBusiness WireSummit Therapeutics Inc. (NASDAQ:SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the
5mo agoSMMTIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in ChinaBusiness WireIvonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall
5mo agoSMMTA hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in ChinaCNBCAn experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
5mo agoSMMTEncouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026Business WirePromising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses Consistent Across Ivonescimab Dose Levels
5mo agoGTBP SMMT IDYA GSK+1B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicPR NewswireUSA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could ...
6mo agoGTBP IDYA RADX SMMTA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyGlobeNewswireIssued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell
6mo agoSMMTSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026Business WireOverall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference Call to be Held on June 1, 2026 after ASCO
7mo agoSMMTMultiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Business WireThree Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the
8mo agoSMMTSummit Therapeutics to Present at Upcoming Investor ConferencesBusiness WireSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team
8mo agoSMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025Business WireHARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 HARMONi-3 Squamous Cohort Enrollment Screening Has
8mo agoSMMTSummit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026Business WireConference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and
9mo agoAVBP SMMT MRUS MRK+9EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightPR NewswireDelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs,...
9mo agoSMMTSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 257,368 shares of
9mo agoSMMTSummit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI TherapyBusiness WireBLA Filing Based on HARMONi Global Phase III Study Results PDUFA Goal Action Date of November 14, 2026 Significant Unmet Need Remains; Over 14,000 U.S. Patients Eligible for Treatment Each Year in This
11mo agoSMMTSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSummit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 67,483 shares of common
1y agoSMMTIvonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in ChinaBusiness WireThe First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates Median OS of 16.8